Company Overview of Cephalon, Inc.
Cephalon, Inc. engages in the discovery and development of medicines for central nervous system disorders, pain, and cancer. It offers NUVIGIL (armodafinil) tablets for improving wakefulness in patients with excessive sleepiness associated with treated obstructive sleep apnea and shift work disorder, also known as shift work disorder and narcolepsy; TREANDA (bendamustine HCl) for injection for the treatment of patients with chronic lymphocytic leukemia; and AMRIX (Cyclobenzaprine Hydrochloride extended-release capsules), which is indicated as an adjunct to rest and physical therapy for relief of muscle spasm associated with acute and painful musculoskeletal conditions. The company also provi...
41 Moores Road
Frazer, PA 19355
Founded in 1987
Key Executives for Cephalon, Inc.
Chief Executive Officer and Director
Chief Financial Officer, Principal Accounting Officer and Executive Vice President
Executive Vice President and President of Cephalon Europe Operations
Executive Vice President, Secretary and General Counsel
Chief Medical Officer and Executive Vice President
Compensation as of Fiscal Year 2014.
Cephalon, Inc. Key Developments
FTC Reaches Settlement with Cephalon Resolving the Commission's Antitrust Suit
May 28 15
The Federal Trade Commission has reached a settlement resolving the Commission's antitrust suit charging Cephalon, Inc. with illegally blocking generic competition to its blockbuster sleep-disorder drug Provigil. The settlement ensures that Teva Pharmaceutical Industries Ltd., which acquired Cephalon in 2012, will make a total of $1.2 billion available to compensate purchasers, including drug wholesalers, pharmacies, and insurers, who overpaid because of Cephalon's illegal conduct. Some of these purchasers have settled related litigation and payments made by Teva in those or other actions can be credited against the FTC fund according to the terms of the stipulated order for equitable monetary relief. Any remaining funds will be paid to the U.S. Treasury. As part of the settlement, Teva also has agreed to a prohibition on the type of anticompetitive patent settlements that Cephalon used to artificially inflate the price of Provigil.
Actavis plc Inks Deal with Cephalon Settling Nuvigil Patent Challenge
May 30 14
Actavis entered into an agreement with Cephalon, Inc. to settle all outstanding patent litigation related to Actavis' generic version of Nuvig (armodafinil tablets, 50 mg, 100 mg, 150 mg, 200 mg and 250 mg). Nuvigil is a prescription medicine indicated to improve wakefulness in adult patients with excessive sleepiness associated with obstructive sleep apnea (OSA), shift work disorder (SWD) or narcolepsy. Under the terms of the agreement, Cephalon will grant Actavis a license to market generic versions of 100 mg and 200 mg Nuvigil beginning on June 1, 2016, or earlier under certain circumstances. Cephalon will also grant Actavis a license to market generic versions of 50 mg, 150 mg and 250 mg NuvigilÃ Â® beginning 180 days after the initial launch of generic versions of those dosage strengths. Other details of the settlement were not disclosed.
O.C. and Santa Clara County Sue Makers of Painkillers, Accusing Them of a Campaign of Deception
May 22 14
Two California counties sued five of the narcotics manufacturers, accusing the companies of causing the nation's prescription drug epidemic by waging a 'campaign of deception' aimed at boosting sales of potent painkillers such as OxyContin. Officials from Orange and Santa Clara counties both hit hard by overdose deaths, emergency room visits and escalating medical costs associated with prescription narcotics contend the drug makers violated California laws against false advertising, unfair business practices and creating a public nuisance. The lawsuit alleges the drug companies have reaped blockbuster profits by manipulating doctors into believing the benefits of narcotic painkillers outweighed the risks, despite a wealth of scientific evidence to the contrary. The effort opened the floodgates for such drugs and the result has been catastrophic. The complaint accuses the companies of encouraging patients, including well-insured veterans and the elderly, to ask their doctors for the painkillers to treat common conditions such as headaches, arthritis and back pain. The widespread prescribing of narcotics has created a population of addicts and triggered a resurgence in the use of heroin, which produces a similar high to opiate-based painkillers, but is cheaper, the suit said. The 100-page lawsuit brought on behalf of the entire state seeks compensation for the damages allegedly caused by the drugs, as well as a court order forcing the companies to forfeit revenue based on the contested marketing campaign. Named in the suit are: Actavis, Endo Health Solutions Inc., Janssen Pharmaceuticals, Purdue Pharma, and Teva Pharmaceutical Industries' Cephalon Inc. The counties allege in the lawsuit that the drug manufacturers broadly promoted the entire class of narcotic painkillers as safer than they are. The marketing campaign promised unproven benefits such as improved sleep and quality of life hat went beyond the claims the FDA allowed the companies to make in marketing specific drugs. The companies employed tactics similar to those used by the tobacco industry to conceal their deceptive marketing and conspiratorial behavior, the suit states.
Similar Private Companies By Industry
Recent Private Companies Transactions